Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial-Reference-Cited by-同舟云学术

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

Published:2020-10 Issue:1 Volume:159 Page:150-156
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Oaknin Ana,Friedman Claire F.,Roman Lynda D.,D'Souza Anishka,Brana Irene,Bidard François-Clement,Goldman Jonathan,Alvarez Edwin A.,Boni Valentina,ElNaggar Adam C.,Passalacqua Rodolfo,Do Khanh T.M.,Santin Alessandro D.,Keyvanjah Kiana,Xu Feng,Eli Lisa D.,Lalani Alshad S.,Bryce Richard P.,Hyman David M.,Meric-Bernstam Funda,Solit David B.,Monk Bradley J.

Funder

Puma Biotechnology Inc

Clovis Oncology

Roche

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference39 articles.

1. Cervical cancer: a global health crisis;Small;Cancer,2017

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

3. International Federation of Gynecology and Obstetrics Global Declaration on cervical Cancer elimination;FIGO World Congress;Rev. Bras. Ginecol. Obstet.,2019